Atherosclerosis is one type of cardiovascular disease (CVD) in which activation of the
NLRP3 inflammasome and toll-like receptor (TLR) pathways is implicated. One of the most …

Poly (lactic‐co‐glycolic acid)(PLGA) nanoparticles (NPs) are commonly used for drug
delivery because of their favored biocompatibility and suitability for sustained and controlled …

Atherosclerosis is a common pathology present in many cardiovascular diseases. Although
the current therapies (including statins and inhibitors of the serine protease PCSK9) can …

Inflammation is intimately involved at all stages of atherosclerosis and remains a substantial
residual cardiovascular risk factor in optimally treated patients. The proof of concept that …

Considering that intravascular reactive oxygen species (ROS) and inflammation are two
characteristic features of the atherosclerotic microenvironment, developing an appropriate …

Inflammation is a key mechanism of cardiovascular diseases. It is an essential component of
atherosclerosis and a significant risk factor for the development of cardiovascular events. In …

Because of their rare detection in atherosclerotic lesions, the involvement of neutrophils in
the pathophysiology of atherosclerosis has been largely denied. However, over the past …

Atherosclerotic vascular disease (ASVD) is a chronic process, with a progressive course
over many years, but it can cause acute clinical events, including acute coronary syndromes …

Intestinal farnesoid X receptor (FXR) signaling is involved in the development of obesity,
fatty liver disease, and type 2 diabetes. However, the role of intestinal FXR in atherosclerosis …

Obesity-driven chronic inflammation and impaired fibrinolysis appear to be major effector
mechanisms of thrombosis in obesity. The proinflammatory and hypofibrinolytic effects of …